GlassScriptPhysician profile
Chhay H Tay
NPI 1962460741
$30,503.41
in general payments reported to CMS, 2019-2025
48 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,685 · 2021: $513 · 2022: $556 · 2023: $573 · 2024: $743 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14,994.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $7,667.77 | 2019-2025 | Farxiga |
| Abbvie INC. | $3,685.17 | 2019-2025 | Vraylar |
| Novo Nordisk INC | $783.87 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $445.98 | 2019-2025 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $308.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $258.10 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.00 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $186.03 | 2023-2025 | |
| Dexcom, INC. | $157.55 | 2022-2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.60 | 2019-2024 | Cycloset |
| Radius Health, INC. | $119.65 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $80.92 | 2022-2023 | Tepezza |
| Abbott Laboratories | $74.32 | 2019-2024 | Freestyle Libre 3 |
| Valeritas, INC. | $74.24 | 2019 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chhay Tay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.